Completed PHASE3 INTERVENTIONAL 6-arm NCT01878422

Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa)

SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS BEVACIZUMAB WITH OR WITHOUT CETUXIMAB AS SECOND-LINE THERAPY

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Conditions Metastatic Colorectal Cancer

Interventions Arm A: FOLFIRI or FOLFOX + Bevacizumab Arm B: FOLFIRI or FOLFOX Arm D: FOLFIRI or FOLFOX plus CETUXIMAB Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB

Updated 8 times since 2017 Last updated: Jan 29, 2025 Started: Nov 30, 2007 Primary completion: Mar 31, 2014 Completion: Jun 11, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01878422, this PHASE3 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE3
Feb 2025 — Apr 2025 [monthly]

Completed PHASE3
Sep 2024 — Feb 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Dec 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Data source: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alba, Italy , Asti, Italy , Belluno, Italy , Bologna, Italy , Brindisi, Italy , Carpi, Italy , Cattolica, Italy , Cesena, Italy , Faenza, Italy , Ferrara, Italy and 10 more locations